---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-025291"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:47:26.828560+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology Q3 net loss widens to $44.7M; product revenue falls 12%

## Summary
- Q3 product revenue $43.4M, down from $49.3M YoY; COVID-19 impact and inventory reduction of ~$3.5M.
- GAAP net loss $44.7M ($1.09/share) vs $31.5M ($0.79/share) in Q3 2020; non-GAAP adj. loss $40.4M.
- Cash, cash equivalents, and marketable securities $87.5M at Sep 30; operating cash flow $10.5M positive.
- Nine-month 2021 total revenue $197.8M included $50M upfront from Pierre Fabre for Greater China rights.
- Milestones: SUMMIT trial data, FDA Type C meeting for accelerated approval in HER2-mutated breast cancer, regulatory decisions.

## SEC filing metadata
- accession: 0001437749-21-025291
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774921025291/0001437749-21-025291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774921025291/pbyi20211103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-025291
- JSON: https://secwatch.observer/filing/0001437749-21-025291.json
- Plain text: https://secwatch.observer/filing/0001437749-21-025291.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.